Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Safety Board Discusses Criteria For Releasing Emerging Safety Info

This article was originally published in The Pink Sheet Daily

Executive Summary

Board considers past actions regarding Shire’s Adderall and erectile dysfunction drugs in attempting to establish method for informing public of safety concerns.
Advertisement

Related Content

Drug Safety Board Adds Staffers With CDER Experience
Drug Safety Board Adds Staffers With CDER Experience
FDA Approves "Unprecedented" Risk Management Program For Accutane
FDA Drug Safety Board To Meet Every Six Weeks
Erectile Dysfunction Class Labeling Does Not Assert Causal Link To Vision Loss
Shire Adderall XR Sales Suspended In Canada; FDA Stands By "Black Box"
Shire Adderall XR Sales Suspended In Canada; FDA Stands By "Black Box"

Topics

Advertisement
UsernamePublicRestriction

Register

PS062930

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel